« Back to Research Deepdives

Can a ‘Nutracuetical’ Lower LDL-cholesterol Levels?

This content is restricted to members.

To view our premium content, sign up for a membership:


Register New Account

Choose your membership level

Choose Your Payment Method

‹ Back to Research Deepdives


  1. Ference B, Ginsberg H, Graham I, Ray K, Packard C, Bruckert E et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. European Heart Journal. 2017;38(32):2459-2472.
  2. Ference B. Causal Effect of Lipids and Lipoproteins on Atherosclerosis. Cardiology Clinics. 2018;36(2):203-211.
  3. Nissen S, Nicholls S, Sipahi I, Libby P, Raichlen J, Ballantyne C et al. Effect of Very High-Intensity Statin Therapy on Regression of Coronary Atherosclerosis – the ASTEROID Trial. JAMA. 2006;295(13):1556.
  4. Boekholdt S, Hovingh G, Mora S, Arsenault B, Amarenco P, Pedersen T et al. Very Low Levels of Atherogenic Lipoproteins and the Risk for Cardiovascular Events. Journal of the American College of Cardiology. 2014;64(5):485-494.
  5. Ference B, Yoo W, Alesh I, Mahajan N, Mirowska K, Mewada A et al. Effect of Long-Term Exposure to Lower Low-Density Lipoprotein Cholesterol Beginning Early in Life on the Risk of Coronary Heart Disease. Journal of the American College of Cardiology. 2012;60(25):2631-2639.
  6. Ference B, Majeed F, Penumetcha R, Flack J, Brook R. Effect of Naturally Random Allocation to Lower Low-Density Lipoprotein Cholesterol on the Risk of Coronary Heart Disease Mediated by Polymorphisms in NPC1L1, HMGCR, or Both. Journal of the American College of Cardiology. 2015;65(15):1552-1561.
  7. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). 2019 ESC/EAS Guidelines for themanagement of dyslipidaemias: lipid modification to reduce cardiovascular risk. Revista Española de Cardiología (English Edition). 2020;73(5):403.
  8. Lu Z, Kou W, Du B, Wu Y, Zhao S, Brusco O et al. Effect of Xuezhikang, an Extract From Red Yeast Chinese Rice, on Coronary Events in a Chinese Population With Previous Myocardial Infarction. The American Journal of Cardiology. 2008;101(12):1689-1693.
  9. Musa-Veloso K, Poon T, Elliot J, Chung C. A comparison of the LDL-cholesterol lowering efficacy of plant stanols and plant sterols over a continuous dose range: Results of a meta-analysis of randomized, placebo-controlled trials. Prostaglandins, Leukotrienes and Essential Fatty Acids. 2011;85(1):9-28.
  10. Reiner Ž, Tedeschi-Reiner E, Romić Ž. Effects of Rice Policosanol on Serum Lipoproteins, Homocysteine, Fibrinogen and C-Reactive Protein in Hypercholesterolaemic Patients. Clinical Drug Investigation. 2005;25(11):701-707.
  11. Ridker P, Mora S, Rose L. Percent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agents. European Heart Journal. 2016;37(17):1373-1379.
  12. Silverman M, Ference B, Im K, Wiviott S, Giugliano R, Grundy S et al. Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions. JAMA. 2016;316(12):1289.